Lapatinib is able to penetrate brain metastases from HER2-positive breast cancer. We assessed lapatinib concentration in cerebrospinal fluid (CSF) of two patients with HER2-positive metastatic breast cancer and brain metastases, and we found low levels of the drug in CSF of both patients. Lapatinib concentration in CSF may not be a reliable surrogate of its distribution in brain metastases.
Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases
Lunardi G;Del Mastro L;
2014-01-01
Abstract
Lapatinib is able to penetrate brain metastases from HER2-positive breast cancer. We assessed lapatinib concentration in cerebrospinal fluid (CSF) of two patients with HER2-positive metastatic breast cancer and brain metastases, and we found low levels of the drug in CSF of both patients. Lapatinib concentration in CSF may not be a reliable surrogate of its distribution in brain metastases.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Ann oncol lapatinib.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
63.08 kB
Formato
Adobe PDF
|
63.08 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
